Genetic deletion of Fincor completely abrogates the therapeutic effects of tofexiflex, including: (1) attenuation of hepatic steatosis via SREBP1c downregulation; (2) inhibition of fibrogenesis through TGF-β pathway suppression; and (3) resolution of lobular inflammation via CCL2/MCP-1 inhibition (19). Here, CCL2 is linked to steatosis.